Topics

Musculoskeletal diseases

Environmental health Research 7 July 2025 Open Access

Bone health perspectives among Indigenous people: a qualitative study

Increasing bone health awareness by a co-created Community education program was valued by Indigenous people

Troy Walker (Yorta Yorta) · Karan P Singh · Vanessa Gan · Brooke Conley (Ngiyampaa) · Jessica Bravo · Nigel Smith (Weilwan) · April Clarke (Eastern Maar, Kirrae Whurrung, Djap Wurrung) · Jackson Baker · Louise J Maple‐Brown · Robin M Daly · Jennifer Browne · Jesse Zanker · Cat Shore‐Lorenti · David Scott · Peter R Ebeling · Ayse Zengin

Mja2 52704

2024 Royal Australian College of General Practitioners and Healthy Bones Australia guideline for osteoporosis management and fracture prevention in postmenopausal women and men over 50 years of age

Poor bone health is highly treatable with appropriate widely available lifestyle and dietary measures and pharmacological agents; the updated guideline is an evidence-based pragmatic tool to assist general practitioners in the day-to-day care of such patients in partnership with bone specialists

Peter Wong · Weiwen Chen · Dan Ewald · Christian Girgis · Morton Rawlin · John Tsingos · Justine Waters

Mja2 52637
Musculoskeletal diseases Editorial 19 August 2024 Open Access

Ensuring a fit‐for‐purpose resource for consumers, clinicians and health services: the updated Osteoarthritis of the Knee Clinical Care Standard

The updated Clinical Care Standard is an important tool that can support best practice care for people with knee osteoarthritis

Ilana N Ackerman · Fiona Doukas · Rachelle Buchbinder · Sally Dooley · Wendy Favorito · Phoebe Holdenson Kimura · David J Hunter · James Linklater · John B North · Louise Elvin‐Walsh · Christopher Vertullo · Alice L Bhasale · Samantha Bunzli

Musculoskeletal diseases Research 18 March 2024 Open Access

Expanding access to fracture liaison services in Australia for people with minimal trauma fractures: a system dynamics modelling study

Changing key FLS operational characteristics would only moderately reduce minimal trauma fractures among people aged 50 years or more

Alicia R Jones · Danielle Currie · Cindy Peng · Peter R Ebeling · Jackie R Center · Gustavo Duque · Sean Lybrand · Greg Lyubomirsky · Rebecca J Mitchell · Sallie Pearson · Markus J Seibel · Jo‐An Occhipinti

Mja2 52241
Endocrinology Guideline summary 13 November 2023 Open Access

Australian evidence‐based guidelines for the prevention and management of diabetes‐related foot disease: a guideline summary

Despite the large national DFD burden, Australian regions implementing guideline-based care have demonstrated large reductions in their regional DFD burdens and costs

Peter A Lazzarini · Anita Raspovic · Jenny Prentice · Robert J Commons · Robert A Fitridge · James Charles · Jane Cheney · Nytasha Purcell · Stephen M Twigg

Mja2 52136

Introducing Australia's clinical care standard for low back pain

A new clinical care standard provides evidence-based guidance to help clinicians deliver best care for people with low back pain

Christopher G Maher · Aline Archambeau · Rachelle Buchbinder · Simon D French · Julie Morphet · Michael K Nicholas · Peter O'Sullivan · Marie Pirotta · Michael J Yelland · Leo Zeller · Nivene Saad · Elizabeth Marles · Alice L Bhasale · Christina Lane

Mja2 51915

Vertebral fractures after denosumab discontinuation for dental procedures: a consequence of distorted perceptions of risk

To the Editor: Khatri’s and Stuckey’s1 article, Vertebral fractures after denosumab discontinuation for dental procedures: a consequence of distorted perceptions of risk, sums up the authors’ knowledge and experience of medication‐related osteonecrosis of the jaws (MRONJ) in the latter part of the title. They quote the risk of MRONJ as being very low and equal for denosumab and oral bisphosphonates. This is incorrect. The risk of MRONJ is 0.3%.2 In our study we found the risk following extractions at 1.8%.3 The recent 2022 update of the position paper on MRONJ4 found that the risk with denosumab is an order of magnitude higher than for bisphosphonates. There is no discussion in Khatri’s and Stuckey’s article1 of the effect of MRONJ on patients. A patient with stage 3 or end‐stage MRONJ has months of severe pain and requires jaw resection with or without microvascular reconstruction similar to that required for advanced jaw cancer.4,5 The impact of this is similar to vertebral collapse, both largely avoidable disasters. The current Australian recommendations for dental extractions for patients taking denosumab for osteoporosis are to delay extractions to 6 months after the last injection of denosumab and then to allow 4weeks for initial socket healing before the next injection.6 The risk is greater if the patient has been taking antiresorptives for more than 4years and if they are immunocompromised.4,7 We would agree that education and communication between prescribers, patients and dentists are key. This can only be achieved by close, mutually respectful communication and understanding between medical, dental, oral and maxillofacial surgeons and patients. However, this is easier to say than put into meaningful practice. Most definitive articles on MRONJ are in oral and maxillofacial surgery journals, which are not commonly read by physicians who prescribe antiresorptives. The most likely reason that the patient was taken off denosumab for 5 months was that the dental plan was not only to extract the teeth but to replace them with dental implants. Implants require time for osseointegration.8 Hopefully, this letter helps correct the distorted precepts expressed by Khatri and Stuckey for prescribers of this, otherwise, useful drug.

Alastair Goss

Mja2 51681

Subscribe to MJA email alerts

No spam, you can unsubscribe anytime you want.

By providing your information, you agree to our Terms of Use and our Privacy Policy.

Thanks for Subscribing! Tell us more

Your email updates will use your name.

Good one! Your updates are coming

Thank you for subscribing to the MJA email alerts. Receive the latest content in your inbox.